Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

27 May 2015

Abstract excerpt

Hyperexpression of antiapoptotic BCL-2 family proteins allows cells to survive despite the receipt of signals that would ordinarily induce their deletion, a facet frequently exploited by tumors. Tumors addicted to the BCL-2 family proteins for survival are now being targeted therapeutically. For example, navitoclax, a BCL-2/BCL-XL/BCL-W inhibitor, is currently in phase I/II clinical trials in numerous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26013319
DOI: 10.1158/1535-7163.mct-14-0928

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule InhibitorPMID 26013319Read ↗

Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic functionSemantic proximity Read ↗

Toward Targeting Antiapoptotic MCL-1 for Cancer TherapySemantic proximity Read ↗

MCL-1 is a clinically targetable vulnerability in breast cancerSemantic proximity Read ↗

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>Semantic proximity Read ↗

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.Semantic proximity Read ↗

Modulating the Bcl-2 Family of Apoptosis Suppressors for Potential Therapeutic Benefit in CancerSemantic proximity Read ↗

Attacking cancer's Achilles heel: antagonism of anti‐apoptotic <scp>BCL</scp>‐2 family membersSemantic proximity Read ↗

MCL-1 is a prognostic indicator and drug target in breast cancerSemantic proximity Read ↗

Mcl-1 inhibitors: a patent reviewSemantic proximity Read ↗

BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of ApoptosisSemantic proximity Read ↗

Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonistsSemantic proximity Read ↗

The multiple mechanisms of MCL1 in the regulation of cell fateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.